Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: LonZim, Lees Foods, blinkx ...

Wed, 27th May 2009 07:59

Zimbabwe-focused investment company LonZim said it is well-placed to benefit from any upturn in the southern African country's economy after investing in several sectors in the six months to February 28.The company posted a pre-tax loss of £911,000 as it invested in telecoms, aviation and hotel sectors."We are positive that the investment potential in Zimbabwe remains strong and that Zimbabwe has a very bright future as it looks to re-establish its presence as one of the major economies on the African continent," said chairman David Lenigas.Scottish cake and sweet supplier Lees Foods saw profits fall sharply in 2008 as it felt the impact of the collapse of the retail chain Woolworths and high raw material, power and distribution costs.Underlying pre-tax profits fell to £402,000 from £721,000 the previous year even as turnover climbed 8% to £16.1m."The fall in profits was primarily a result of a bad debt provision of £69,000 which was owed to the company by Woolworths and a significant increase in raw materials, power and distribution costs," Lees said.The board is recommending the dividend be maintained at 6.7p a share.Video search engine specialist blinkx has signed an agreement with US sport site FOXSports.com to add almost 1,000 video clips of sporting contests to its searchable video library. Globus Maritime saw gross revenues of $11.8m against $24m in the same period last year, while EBITDA was $7m against $18.8m.AIM-listed Africa-focused gas company Gasol has successfully raised £1m through a placing of shares with two of its principal shareholders, African Gas Development Corporation and Afren.Shares in Vyke Communications were marked lower Wednesday after the company said it issued 0.26m shares to settle supplier invoices totalling 1.75m Norwegian kroner. The newly issued shares represent 0.4% of Vyke's existing issued share capital.Smoker's cough treatment specialist Synairgen has raised £6.35m through a placing and subscription at 17p per share. The proceeds will finance two planned Phase IIa inhaled interferon beta studies in asthma and COPD.Bus maker Optare slipped into a loss £12m in 2008 reflecting costs of integrating two new businesses in difficult trading conditions. Turnover for the year was £49.2m (pro forma £82.4m) and loss from operations was £4.0m (pro forma £3.0m). Programme maker Shed Media has appointed Heather Rabbatts, Millwall FC's executive deputy chairman, as its new chairman. Coline McConville, who sat on the board of HBOS until early this year, and Marc Watson, from BT, are also joining as non-execs. Celebrity agent Formation Group saw profit before tax edge up to £1.83m in the six months ended 28 February from £1.76m a year ago on revenue from continuing operations of £18.8 versus £12.8m last time.The shares rallied yesterday after the group, whose clients include Simon Cowell and TV presenters Ant and Dec, confirmed it has received indications of interest from private equity group Gresham over 'certain parts' of the business. IFA Cavanagh's underlying profits fell to £779,000 (2007: £1.61m) on revenue of £17.5m (2007: £16.6m)in 2008. " Against a backdrop of what has probably been the most volatile period experienced in the financial markets since the 1930s, I consider this to be a satisfactory performance," chairman Paul Sinnet said.Powered glass specialist Romag posted an underlying loss of £1.3m in the half -year to March in what the company describes as the toughest conditions it has seen for 60 years. Unless conditions turned in the next few weeks it is unlikely it will be able to repeat the strong performance in sales and profits achieved in the second half of last year. Interim sales were 12% down at £10.2m, though a £2.7m currency hedging gain enabled it post a £1.1m profit.
More News
6 Jan 2022 14:51

IN BRIEF: Synairgen signs partnership for its Covid-19 treatment in US

IN BRIEF: Synairgen signs partnership for its Covid-19 treatment in US

Read more
11 Nov 2021 18:36

TRADING UPDATES: Avation sells Airbus jet; Mode Global's bitcoin deal

TRADING UPDATES: Avation sells Airbus jet; Mode Global's bitcoin deal

Read more
11 Nov 2021 13:03

Synairgen secures patients for phase III study of Covid treatment, shares jump

(Sharecast News) - Shares in Synairgen rallied on Thursday,after the respiratory drug specialist confirmed it was starting a Phase III study into a potential Covid-19 treatment.

Read more
20 Oct 2021 11:14

IN BRIEF: Synairgen Covid treatment pushed for phase 3 trials by Activ

IN BRIEF: Synairgen Covid treatment pushed for phase 3 trials by Activ

Read more
20 Oct 2021 10:56

AIM WINNERS & LOSERS: Arena soars on takeover; Accrol supply chain hit

AIM WINNERS & LOSERS: Arena soars on takeover; Accrol supply chain hit

Read more
30 Sep 2021 14:42

EARNINGS UPDATES: President Energy slims loss; Jangada turns a profit

EARNINGS UPDATES: President Energy slims loss; Jangada turns a profit

Read more
23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
11 Jun 2021 15:59

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
24 May 2021 12:02

TRADING UPDATES: Digital 9 raises cash; Bluejay and Rio start drilling

TRADING UPDATES: Digital 9 raises cash; Bluejay and Rio start drilling

Read more
24 May 2021 08:33

Synairgen drug proves effective against Covid variants in lab tests

(Sharecast News) - A drug being developed by Synairgen to treat severe lung infections has shown promising laboratory results against emerging variants of Covid-19, the biotech announced on Monday.

Read more
12 May 2021 14:26

TRADING UPDATES: Vertu Motors profit jumps; Mears swings to 2020 loss

TRADING UPDATES: Vertu Motors profit jumps; Mears swings to 2020 loss

Read more
30 Apr 2021 14:15

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump

Read more
15 Feb 2021 11:57

Synairgen confirms start of dosing in Covid-19 trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Monday that dosing has started in the inhaled interferon beta formulation 'SNG001' sub-study of the 'ACTIV-2' phase 2 and 3 trial, evaluating patients with mild-to-moderate Covid-19 symptoms not yet requiring hospitalisation.

Read more
15 Feb 2021 10:52

IN BRIEF: Synairgen Begins Dosing Of Covid Patients In SNG001 Sub-Study

IN BRIEF: Synairgen Begins Dosing Of Covid Patients In SNG001 Sub-Study

Read more
25 Jan 2021 19:18

TRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic

TRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.